In 2017, RBV Capital acquired an equity stake in an innovative UK-based company developing an asset for treating symptoms of multiple sclerosis. Later in 2017, the company received poor results of the clinical trial of its sole asset: the efficacy of the treatment wasn’t statistically different from placebo. Further financing from all investors, including leading...Read More
Allergan plc (NYSE: AGN ), a leading global pharmaceutical company, today announced it has agreed to acquire Bonti, Inc., a privately held clinical-stage biotechnology company focused on the development and commercialization of novel, fast-acting neurotoxin programs for aesthetic and therapeutic applications. Following completion of the acquisition, Allergan will obtain global rights to Bonti’s pipeline consisting of two...Read More
Allergan plc (NYSE: AGN), a leading global pharmaceutical company, and RetroSense Therapeutics LLC, a private, clinical-stage biotechnology company focused on novel gene therapy approaches to restore vision in patients suffering from blindness, today announced that Allergan has acquired substantially all of the assets of RetroSense in an all-cash transaction. Under the terms of the transaction,...Read More
We are using cookies to give you the best experience. You can find out more about which cookies we are using or switch them off in privacy settings.
